Test for Diagnosing Fibrolamellar Carcinoma Yields 100-Percent Accuracy

fibrolamellar carcinoma

Mayo Clinic researchers recently developed an RT-PCR assay along with a break-apart FISH assay that can diagnose fibrolamellar carcinoma 100 percent of the time. The assays can detect the novel fusion at the transcriptional and genomic level, respectively, and could also help researchers learn more about liver tumor biology.

Fibrolamellar carcinoma is a rare subtype of hepatocellular carcinoma—the most common type of liver cancer. There are approximately 50 new cases of fibrolamellar carcinoma diagnosed per year in the U.S., which predominantly affects young patients without underlying cirrhosis (most conventional liver cancers arise in cirrhotic livers). The tumor is characterized by a unique intratumoral fibrosis that often has a lamellar pattern and large eosinophilic cells. Recently, a recurrent fusion gene, DNAJB1-PRKACA, was reported in fibrolamellar carcinomas. However, the specificity of this fusion in the context of other primary liver neoplasms remained unknown.

In the Mayo Clinic study, published in Modern Pathology, a total of 26 fibrolamellar carcinomas were reviewed, including 19 cases from Mayo Clinic and 7 cases from the University Hospital of Heidelberg, Germany. Remarkably, testing confirmed the presence of the DNAJB1-PRKACA fusion in all 26 fibrolamellar carcinomas.

Rondell Graham, M.B.B.S.

“To our surprise, they were all positive,” says Rondell Graham, M.B.B.S., first author on the paper and a fellow in the Department of Laboratory Medicine and Pathology at Mayo. “We had two methods to confirm that our results were really true, the RT-PCR assay and the FISH assay. Those two investigations were done independently by different members of our team. And the results confirmed the DNAJB1-PRKACA fusion gene was one-hundred percent sensitive for fibrolamellar carcinomas.” The fusion is present in essentially all tumor cells, suggesting it is an early mutational event in the development of fibrolamellar carcinoma. Based on a survey of an additional 105 primary liver tumors, the DNAJB1-PRKACA fusion gene appears to be specific, indicating it will be a useful diagnostic assay.

“We intend to make it a clinically available test, probably within a year,” says Dr. Graham. “This test will be used infrequently, but we think it is going to be important. We already know that fibrolamellar carcinoma is over-diagnosed. Also, by accurately diagnosing fibrolamellar carcinoma, we can hopefully understand more about the biology of this and other more common liver cancers. This diagnostic assay really brings us one step closer to that fundamental goal.”

The study results demonstrate that morphologically distinct variants of hepatocellular carcinoma may be associated with unique genetic changes, allowing for a morphology-based subclassification that reflects specific genetic-driver events.

“On a histological level, we recognize that there are subtypes of tumors. We know that all tumors in the kidney or the breast, for example, are not the same, and it has emerged that different histologic subtypes correspond to different genetic changes. What we’re seeing now, with this discovery in fibrolamellar carcinoma, is that the same thing is true for the liver. We believed that this was the case based on morphologic grounds, but now we have genetic evidence.”

Several tumor types, including lung and breast cancer, are currently much further along in terms of targeted therapies when compared to liver cancer. This is in great part because many subtypes of these cancers have been recognized and understood on a histological, morphological, and molecular level. Dr. Graham and the Mayo team of researchers are striving to uncover the subtypes of liver cancer so that ultimately, patients will have more treatment options.

“The only way we can understand subtypes of hepatocellular carcinomas really well is if we can identify them reproducibly and with high accuracy,” says Dr. Graham. “Then, we can improve our grasp of their biology and eventually implement more precisely targeted therapies. This is especially important for hepatocellular carcinoma because current chemotherapy has not been very successful, and patients without surgically resectable disease have a poor outcome.”


Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.

Leave a Reply

Your email address will not be published. Required fields are marked *